001037245 001__ 1037245
001037245 005__ 20250203124512.0
001037245 0247_ $$2doi$$a10.1093/nop/npae061
001037245 0247_ $$2ISSN$$a2054-2577
001037245 0247_ $$2ISSN$$a2054-2585
001037245 0247_ $$2pmid$$a39279772
001037245 0247_ $$2WOS$$aWOS:001288471300001
001037245 037__ $$aFZJ-2025-00578
001037245 082__ $$a610
001037245 1001_ $$0P:(DE-HGF)0$$aTaphoorn, Martin J B$$b0$$eCorresponding author
001037245 245__ $$aEuropean Association of Neuro-Oncology’s 30th anniversary: A successful and growing relationship with Neuro-Oncology Practice
001037245 260__ $$aOxford$$bOxford Univ. Press$$c2024
001037245 3367_ $$2DRIVER$$aarticle
001037245 3367_ $$2DataCite$$aOutput Types/Journal article
001037245 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738147015_7915
001037245 3367_ $$2BibTeX$$aARTICLE
001037245 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001037245 3367_ $$00$$2EndNote$$aJournal Article
001037245 520__ $$aExtractThis month, October 2024, we proudly celebrate the 30th Anniversary of the European Association of Neuro-Oncology (EANO). During our yearly conference, this time in Glasgow, we will look back with many EANO members and colleagues from all over the world to what has been accomplished globally in this unique and challenging oncological subspecialty over the past decades. Diagnosis, treatment, and care for neuro-oncological patients and their families have steadily developed and improved substantially. Thorough (pre)clinical and translational research form the basis for these achievements and guide the training and education for all of us. The achievements are primarily of benefit for our patients and their families, but also for the readership of Neuro-Oncology Practice: practicing healthcare professionals.Neuro-Oncology Practice started as an offspring journal of Neuro-Oncology in 2014 and is dedicated to publishing articles with high relevance for clinical practice, specifically addressing all topics of interest for practicing healthcare professionals. For this goal, the Journal benefits from (invited and unsolicited) reviews, editorials, guidelines, clinical debate, and publication of original research.1–5 To become relevant, both clinical trial data and real-world data need to be interpreted for our readers.6 The same holds true for the key molecular genetics of brain tumors, integrated with histopathology.7 The Response Assessment in Neuro-Oncology (RANO) initiative is another major breakthrough in the field, and it is no longer confined to imaging.8 Clinical outcomes related to functioning and well-being are of equal importance compared to survival and imaging to determine the net clinical benefit of (new) treatments for brain tumor patients.9 With successful treatments, critical issues related to long-term survivorship come along. Tumor-targeted and patient-tailored treatments have eventually become a reality, and caregivers equally deserve our attention and care.10 An upcoming supplement to our journal on the treatment of IDH mutant gliomas will accompany the introduction of IDH inhibitors, which has proved to be the most recent breakthrough.11
001037245 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001037245 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001037245 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b1
001037245 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b2
001037245 7001_ $$0P:(DE-HGF)0$$aPlatten, Michael$$b3
001037245 7001_ $$0P:(DE-HGF)0$$aShort, Susan C$$b4
001037245 773__ $$0PERI:(DE-600)2768945-1$$a10.1093/nop/npae061$$gVol. 11, no. 5, p. 509 - 510$$n5$$p509 - 510$$tNeuro-oncology practice$$v11$$x2054-2577$$y2024
001037245 8564_ $$uhttps://juser.fz-juelich.de/record/1037245/files/post-print.pdf$$yRestricted
001037245 909CO $$ooai:juser.fz-juelich.de:1037245$$pVDB
001037245 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b1$$kFZJ
001037245 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001037245 9141_ $$y2024
001037245 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL PRACT : 2022$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
001037245 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
001037245 920__ $$lyes
001037245 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001037245 980__ $$ajournal
001037245 980__ $$aVDB
001037245 980__ $$aI:(DE-Juel1)INM-3-20090406
001037245 980__ $$aUNRESTRICTED